The study, published in the American Journal of Gastroenterology, analyzed 2.6 million commercial insurance and Medicare Part D claims between May 2022 and April 2023 to monitor how many patients paid out of pocket for bowel prep medications needed for colonoscopy, according to a July 2 news release from the Colon Cancer Coalition, a nonprofit organization.
When considering that almost half of patients are cost-shifted toward the use of non-FDA-approved over-the-counter regimens, the data suggests that only 17% of patients pay nothing for their bowel preparation for screening colonoscopy.
Of the prescription claims analyzed, only 36% had no out-of-pocket costs, according to the release. For Medicare Part D, only 25% of high-volume preps were free.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.